Effect of monthly high-dose vitamin D supplementation on falls and non-vertebral fractures: secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial - PubMed (original) (raw)
Effect of monthly high-dose vitamin D supplementation on falls and non-vertebral fractures: secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial
Kay-Tee Khaw et al. Lancet Diabetes Endocrinol. 2017 Jun.
Abstract
Background: Adults with low concentrations of 25-hydroxyvitamin D (25[OH]D) in blood have an increased risk of falls and fractures, but randomised trials of vitamin D supplementation have had inconsistent results. We aimed to assess the effect of high-dose vitamin D supplementation on fractures and falls.
Methods: The Vitamin D Assessment (ViDA) Study was a randomised, double-blind, placebo-controlled trial of healthy volunteers aged 50-84 years conducted at one centre in Auckland, New Zealand. Participants were randomly assigned to receive either an initial oral dose of 200 000 IU (5·0 mg) colecalciferol (vitamin D3) followed by monthly 100 000 IU (2·5 mg) colecalciferol or equivalent placebo dosing. The prespecified primary outcome was cardiovascular disease and secondary outcomes were respiratory illness and fractures. Here, we report secondary outcome data for fractures and post-hoc outcome data for falls. Cox proportional hazards models were used to estimate hazard ratios (HRs) for time to first fracture or time to first fall in individuals allocated vitamin D compared with placebo. The analysis of fractures included all participants who gave consent and was by intention-to-treat; the analysis of falls included all individuals who returned one or more questionnaires. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12611000402943.
Findings: Between April 5, 2011, and Nov 6, 2012, 5110 participants were recruited and randomly assigned either colecalciferol (n=2558) or placebo (n=2552). Two participants allocated placebo withdrew consent after randomisation; thus, a total of 5108 individuals were included in the analysis of fractures. The mean age of participants was 65·9 years (SD 8·3) and 2971 (58%) were men. The mean concentration of 25(OH)D in blood was 63 nmol/L (SD 24) at baseline, with 1534 (30%) having 25(OH)D concentrations lower than 50 nmol/L. Follow-up was until July 31, 2015, with a mean treatment duration of 3·4 years (SD 0·4, range 2·5-4·2). During follow-up, 2638 participants reported having a fall, 1312 (52%) of 2539 in the vitamin D group compared with 1326 (53%) of 2517 in the placebo group. The HR for falls-adjusted for age, sex, ethnic origin, history of recent fall, physical activity, and baseline 25(OH)D-was 0·99 (95% CI 0·92-1·07; p=0·82) for vitamin D compared with placebo. Non-vertebral fractures were reported in 292 individuals, 156 (6%) of 2558 in the vitamin D group and 136 (5%) of 2550 in the placebo group. The adjusted HR for fractures was 1·19 (95% CI 0·94-1·50; p=0·15) for vitamin D compared with placebo. 123 (2%) people died during the trial, 65 assigned vitamin D and 58 allocated placebo; the difference between treatment groups was not significant.
Interpretation: High-dose bolus vitamin D supplementation of 100 000 IU colecalciferol monthly over 2·5-4·2 years did not prevent falls or fractures in this healthy, ambulatory, adult population. Further research is needed to ascertain the effects of daily vitamin D dosing, with or without calcium.
Funding: Health Research Council of New Zealand and Accident Compensation Corporation of New Zealand.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Comment in
- Can vitamin D prevent falls and fractures?
Bouillon R. Bouillon R. Lancet Diabetes Endocrinol. 2017 Jun;5(6):407-409. doi: 10.1016/S2213-8587(17)30140-7. Epub 2017 Apr 28. Lancet Diabetes Endocrinol. 2017. PMID: 28461160 No abstract available.
Similar articles
- High-dose oral vitamin D supplementation and mortality in people aged 65-84 years: the VIDAL cluster feasibility RCT of open versus double-blind individual randomisation.
Rake C, Gilham C, Bukasa L, Ostler R, Newton M, Peto Wild J, Aigret B, Hill M, Gillie O, Nazareth I, Sasieni P, Martineau A, Peto J. Rake C, et al. Health Technol Assess. 2020 Feb;24(10):1-54. doi: 10.3310/hta24100. Health Technol Assess. 2020. PMID: 32090730 Free PMC article. Clinical Trial. - Monthly High-Dose Vitamin D Supplementation and Cancer Risk: A Post Hoc Analysis of the Vitamin D Assessment Randomized Clinical Trial.
Scragg R, Khaw KT, Toop L, Sluyter J, Lawes CMM, Waayer D, Giovannucci E, Camargo CA Jr. Scragg R, et al. JAMA Oncol. 2018 Nov 1;4(11):e182178. doi: 10.1001/jamaoncol.2018.2178. Epub 2018 Nov 8. JAMA Oncol. 2018. PMID: 30027269 Free PMC article. Clinical Trial. - Overview of results from the Vitamin D Assessment (ViDA) study.
Scragg RKR. Scragg RKR. J Endocrinol Invest. 2019 Dec;42(12):1391-1399. doi: 10.1007/s40618-019-01056-z. Epub 2019 May 23. J Endocrinol Invest. 2019. PMID: 31124042 Clinical Trial. - Effectiveness and safety of vitamin D in relation to bone health.
Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V. Cranney A, et al. Evid Rep Technol Assess (Full Rep). 2007 Aug;(158):1-235. Evid Rep Technol Assess (Full Rep). 2007. PMID: 18088161 Free PMC article. Review. - Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials.
Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Bischoff-Ferrari HA, et al. JAMA. 2005 May 11;293(18):2257-64. doi: 10.1001/jama.293.18.2257. JAMA. 2005. PMID: 15886381 Review.
Cited by
- Vitamin D supplementation and falls in residential aged care: A longitudinal multisite cohort study.
Wabe N, Meulenbroeks I, Firempong DC, Raban MZ, Nguyen AD, Close JT, Lord SR, Westbrook JI. Wabe N, et al. Bone Rep. 2024 Jul 23;22:101791. doi: 10.1016/j.bonr.2024.101791. eCollection 2024 Sep. Bone Rep. 2024. PMID: 39139591 Free PMC article. - Vitamin D therapy in chronic kidney disease: a critical appraisal of clinical trial evidence.
Yeung WG, Toussaint ND, Badve SV. Yeung WG, et al. Clin Kidney J. 2024 Jul 18;17(8):sfae227. doi: 10.1093/ckj/sfae227. eCollection 2024 Aug. Clin Kidney J. 2024. PMID: 39119524 Free PMC article. Review. - Effect of vitamin D on risk of falls and fractures - The contribution of recent mega-trials.
Dawson-Hughes B. Dawson-Hughes B. Metabol Open. 2024 Jul 16;23:100300. doi: 10.1016/j.metop.2024.100300. eCollection 2024 Sep. Metabol Open. 2024. PMID: 39100895 Free PMC article. - Effect of vitamin D, calcium, or combined supplementation on fall prevention: a systematic review and updated network meta-analysis.
Tan L, He R, Zheng X. Tan L, et al. BMC Geriatr. 2024 May 2;24(1):390. doi: 10.1186/s12877-024-05009-x. BMC Geriatr. 2024. PMID: 38698349 Free PMC article. - Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.
Giustina A, Bilezikian JP, Adler RA, Banfi G, Bikle DD, Binkley NC, Bollerslev J, Bouillon R, Brandi ML, Casanueva FF, di Filippo L, Donini LM, Ebeling PR, Fuleihan GE, Fassio A, Frara S, Jones G, Marcocci C, Martineau AR, Minisola S, Napoli N, Procopio M, Rizzoli R, Schafer AL, Sempos CT, Ulivieri FM, Virtanen JK. Giustina A, et al. Endocr Rev. 2024 Sep 12;45(5):625-654. doi: 10.1210/endrev/bnae009. Endocr Rev. 2024. PMID: 38676447 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous